TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02336334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positioning measurement
Description: Logging of posturing informations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positioning measurement
Description: Logging of posturing informations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient feedback
Description: Evaluation of patients questionary

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient feedback
Description: Evaluation of patients questionary

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usefulness of a sketch
Description: Helping the patients to understand posturing positions by randomized allocation of sketches

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usefulness of a sketch
Description: Helping the patients to understand posturing positions by randomized allocation of sketches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure rate of macular holes
Description: closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
Study: NCT02895087

Intervention type: OTHER
Intervention: Diurnal Variation Group
Description: This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).

Intervention type: OTHER
Intervention: External Stress Group
Description: 2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit.
Study: NCT01435538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care pathway.
Description: The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
Study: NCT00729833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib - daily dosing
Study: NCT00417079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel (XRP6258) (RPR116258)
Description: 25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: 12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 10 mg daily administered by oral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 10 mg daily administered by oral route
Study: NCT01383733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5458640
Description: Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
Study: NCT01163097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 40 µg/kg IV bolus injections for three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 40 µg/kg IV bolus injections for three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin continuous IV infusion
Study: NCT00999375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification
Study: NCT04403698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Effervescent Oral Tablet
Description: At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Effervescent Oral Tablet
Description: At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
Study: NCT01047839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: 0.25 ml, 2 i.m. vaccinations at Day 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: 0.5 ml, 2 i.m. vaccinations at Day 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
Study: NCT04370873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as dry powder inhalation according to randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as dry powder inhalation according to randomization
Study: NCT01932125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
Study: NCT00792948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant
Study: NCT00459433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsychosocial intervention
Description: Psychosocial versus usual care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial intervention
Description: Psychosocial versus usual care
Study: NCT02973945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Venturi Mask
Description: During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions.
Study: NCT02815618

Intervention type: DEVICE
Intervention: BabyLux Neuro-monitor
Description: Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).

Intervention type: DEVICE
Intervention: BabyLux Neuro-monitor
Description: Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).

Intervention type: DEVICE
Intervention: BabyLux Neuro-monitor
Description: Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
Study: NCT01995149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and dietary intervention
Description: The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
Study: NCT00792948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01662882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq(10mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq(10mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: IV injection, 370 MBq(10mCi), single dose
Study: NCT01775904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in a Capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in an orally disintegrating tablet (ODT)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in an orally disintegrating tablet (ODT)
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721 in an orally disintegrating tablet (ODT)
Description: Administered orally.
Study: NCT04838899

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SABR)
Description: SABR to oligoprogressive metastases while continuing abiraterone therapy
Study: NCT03106818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacain with magnesium sulphate
Description: will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine only
Description: will receive bupivacain 0.125% infusion in the presternum , for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: only conventional post operative analgesics will be used
Study: NCT02160587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloraprep
Description: ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Physiological Saline
Description: 0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep without IPA
Description: ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
Study: NCT04010994

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transorbital electrical stimulation
Description: Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
Study: NCT04560257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula HFNC
Description: High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
Study: NCT00374673

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
Study: NCT03600922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the patella was resurfaced.
Description: Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
Study: NCT01565707

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Urotherapy
Description: Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Urotherapy
Description: Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
Study: NCT04209673

Intervention type: OTHER
Intervention: Multimodal Pain management including TENS unit
Description: Patient receiving multimodal pain management strategies which includes the use of TENS.

Intervention type: OTHER
Intervention: Multimodal Pain management not including TENS unit
Description: Patient receiving multimodal pain management strategies which does not includes the use of TENS.
Study: NCT00661141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antizol
Study: NCT00422786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP-232
Description: Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
Study: NCT06584669

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
Study: NCT01792206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Study: NCT02240940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parachute Implant
Description: CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
Study: NCT02496078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir tablet 60mg
Study: NCT00148616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
Study: NCT02496078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir tablet 60mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asunaprevir
Description: Asunaprevir soft capsule 100 mg
Study: NCT00661141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antizol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antizol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antizol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00148616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
Study: NCT01562821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
Study: NCT00661141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02496078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asunaprevir
Description: Asunaprevir soft capsule 100 mg
Study: NCT01327170

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subthreshold diode micropulse laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subthreshold diode micropulse laser
Study: NCT04210063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
Study: NCT04768816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
Study: NCT01562821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An initial placebo bolus dose followed by placebo every second hour until completion of surgery
Study: NCT00866502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0031
Description: Continuous ICV infusion for two weeks
Study: NCT01039727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual + 5 specific CDs
Description: care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual + email assistance + AurelisOnLine (AoL) + CDs
Description: care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
Study: NCT03279757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 5 minutes
Description: Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 15 minutes
Description: Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 25 minutes
Description: Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 5 minutes
Description: Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density